EDAP TMS Announces Publication Of HIFI-2 Study, Nationwide Trial Evaluating Salvage HIFU Using Focal One Robotic HIFU For Treatment Of Localized Prostate Cancer Recurrence Following Radiotherapy

EDAP TMS SA Sponsored ADR

EDAP TMS SA Sponsored ADR

EDAP

0.00

EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer

AUSTIN, Texas, April 30, 2026 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced the publication of the HIFI-2 study, a large, prospective, nationwide trial evaluating salvage high-intensity focused ultrasound (HIFU) using Focal One Robotic HIFU for the treatment of localized prostate cancer recurrence following radiotherapy.

Published in European Urology Oncology, the study titled "Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study)" represents the largest prospective dataset to date in this clinical setting, including 531 patients treated across more than 30 centers.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.